How have evolutions in strategies for the treatment of relapsed/refractory multiple myeloma translated into improved outcomes for patients?

Pieter Sonneveld; E de Wit; P Moreau

doi:10.1016/j.critrevonc.2017.02.007

How have evolutions in strategies for the treatment of relapsed/refractory multiple myeloma translated into improved outcomes for patients?

Pieter Sonneveld
, E de Wit
, P Moreau

Hematology

Research output: Contribution to journal › Article › Academic › peer-review

38 Citations (Scopus)

32 Downloads (Pure)

Original language	Undefined/Unknown
Pages (from-to)	153-170
Number of pages	18
Journal	Critical Reviews in Oncology/Hematology
Volume	112
DOIs	https://doi.org/10.1016/j.critrevonc.2017.02.007
Publication status	Published - 2017

Research programs

EMC OR-01

Access to Document

10.1016/j.critrevonc.2017.02.007

Repub_108591_O-A.pdfFinal published version, 1.96 MB

http://hdl.handle.net/1765/108591

Cite this

@article{2915299a65db4cb7afe2dff287c43a71,

title = "How have evolutions in strategies for the treatment of relapsed/refractory multiple myeloma translated into improved outcomes for patients?",

author = "Pieter Sonneveld and \{de Wit\}, E and P Moreau",

year = "2017",

doi = "10.1016/j.critrevonc.2017.02.007",

language = "Undefined/Unknown",

volume = "112",

pages = "153--170",

journal = "Critical Reviews in Oncology/Hematology",